TY - JOUR
T1 - A histologic classification of IgA nephropathy for predicting long-term prognosis
T2 - Emphasis on end-stage renal disease
AU - Kawamura, Tetsuya
AU - Joh, Kensuke
AU - Okonogi, Hideo
AU - Koike, Kentaro
AU - Utsunomiya, Yasunori
AU - Miyazaki, Yoichi
AU - Matsushima, Masato
AU - Yoshimura, Mitsuhiro
AU - Horikoshi, Satoshi
AU - Suzuki, Yusuke
AU - Furusu, Akira
AU - Yasuda, Takashi
AU - Shirai, Sayuri
AU - Shibata, Takanori
AU - Endoh, Masayuki
AU - Hattori, Motoshi
AU - Akioka, Yuko
AU - Katafuchi, Ritsuko
AU - Hashiguchi, Akinori
AU - Kimura, Kenjiro
AU - Matsuo, Seiichi
AU - Tomino, Yasuhiko
PY - 2013
Y1 - 2013
N2 - A multicenter case-control study on IgA nephropathy (IgAN) was conducted to develop an evidence-based clinicopathologic classification of IgAN for predicting long-term renal outcome. Methods: Two hundred and eighty-seven patients including those with isolated hematuria or very mild proteinuria were enrolled. During a median follow-up of 9.3 years after biopsy, 49 patients (17%) progressed to end stage renal disease (ESRD). The associations between pathological variables and the need for chronic dialysis was examined by multivariate logistic regression analysis separately in patients who required dialysis earlier than 5 years (Early Progressors) and those who required dialysis within 5 to 10 years (Late Progressors) after biopsy. Results: Independent pathological variables predicting progression to ESRD were global sclerosis, segmental sclerosis and fibrous crescents for Early Progressors, and global sclerosis and cellular/fibrocellular crescents for Late Progressors. Four histological grades, HG 1, HG 2, HG 3 and HG 4, were established corresponding to <25%, 25-49%, 50-74% and ≥75% of glomeruli exhibiting cellular or fibrocellular crescents, global sclerosis, segmental sclerosis or fibrous crescents. Eleven (7%) patients in HG 1, 12 (16%) in HG 2, 13 (31%) in HG 3 and 13 (68%) in HG 4 progressed to ESRD. Multivariate logistic analysis revealed that the risk of progression to ESRD was significantly higher in HG 2, 3 and 4 than in HG 1 (odds ratio, 2.4, 5.7 and 27.6 vs. 1.0). Conclusions: Our evidence-based histologic classification can identify the magnitude of the risk of progression to ESRD and is useful for predicting longterm renal outcome in IgAN.
AB - A multicenter case-control study on IgA nephropathy (IgAN) was conducted to develop an evidence-based clinicopathologic classification of IgAN for predicting long-term renal outcome. Methods: Two hundred and eighty-seven patients including those with isolated hematuria or very mild proteinuria were enrolled. During a median follow-up of 9.3 years after biopsy, 49 patients (17%) progressed to end stage renal disease (ESRD). The associations between pathological variables and the need for chronic dialysis was examined by multivariate logistic regression analysis separately in patients who required dialysis earlier than 5 years (Early Progressors) and those who required dialysis within 5 to 10 years (Late Progressors) after biopsy. Results: Independent pathological variables predicting progression to ESRD were global sclerosis, segmental sclerosis and fibrous crescents for Early Progressors, and global sclerosis and cellular/fibrocellular crescents for Late Progressors. Four histological grades, HG 1, HG 2, HG 3 and HG 4, were established corresponding to <25%, 25-49%, 50-74% and ≥75% of glomeruli exhibiting cellular or fibrocellular crescents, global sclerosis, segmental sclerosis or fibrous crescents. Eleven (7%) patients in HG 1, 12 (16%) in HG 2, 13 (31%) in HG 3 and 13 (68%) in HG 4 progressed to ESRD. Multivariate logistic analysis revealed that the risk of progression to ESRD was significantly higher in HG 2, 3 and 4 than in HG 1 (odds ratio, 2.4, 5.7 and 27.6 vs. 1.0). Conclusions: Our evidence-based histologic classification can identify the magnitude of the risk of progression to ESRD and is useful for predicting longterm renal outcome in IgAN.
KW - End-stage renal disease
KW - IgA nephropathy
KW - Prognosis
KW - Progression
KW - Risk factor
UR - http://www.scopus.com/inward/record.url?scp=84867850113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867850113&partnerID=8YFLogxK
U2 - 10.5301/jn.5000151
DO - 10.5301/jn.5000151
M3 - Article
C2 - 22684645
AN - SCOPUS:84867850113
SN - 1121-8428
VL - 26
SP - 350
EP - 357
JO - Journal of Nephrology
JF - Journal of Nephrology
IS - 2
ER -